Polatuzumab vedotin plus bendamustine and rituximab in patients
with relapsed/refractory diffuse large B-cell lymphoma in the
real world

J 2022

Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world

VODICKA, Prokop, Katerina BENESOVA, Andrea JANÍKOVÁ, Vit PROCHAZKA, David BELADA et. al.

Základní údaje

Originální název

Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world

Autoři

VODICKA, Prokop (203 Česká republika), Katerina BENESOVA (203 Česká republika), Andrea JANÍKOVÁ (203 Česká republika, domácí), Vit PROCHAZKA (203 Česká republika), David BELADA (203 Česká republika), Heidi MOCIKOVA (203 Česká republika), Katerina STEINEROVA (203 Česká republika), Juraj DURAS (203 Česká republika), Josef KARBAN (203 Česká republika), Veronika HANACKOVA (203 Česká republika), Alice SYKOROVA (203 Česká republika), Ales OBR (203 Česká republika) a Marek TRNENY (203 Česká republika, garant)

Vydání

European Journal of Haematology, Hoboken, Wiley-Blackwell, 2022, 0902-4441

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.100

Kód RIV

RIV/00216224:14110/22:00128259

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1111/ejh.13784

UT WoS

000793085400001

Klíčová slova anglicky

DLBCL; polatuzumab vedotin; real world

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 25. 1. 2023 09:54, Mgr. Tereza Miškechová

Anotace

V originále

Objectives Polatuzumab vedotin with bendamustine and rituximab (Pola-BR) was approved for treatment of transplant-ineligible patients with relapsed/refractory DLBCL (R/R DLBCL). However, the number of patients treated in the GO29365 trial including the extension cohort was limited, and more data evaluating the efficacy of this treatment regimen is needed. Methods We analyzed 21 patients with R/R DLBCL to determine real-life efficacy and safety of Pola-BR regimen. Data of all patients entered the database of the NiHiL project (NCT03199066). Results Median overall survival was 8.7 months, and progression-free survival 3.8 months. The overall response rate was 33%. Grade 3-4 neutropenia was detected in 29%, thrombocytopenia in 38%, anemia in 19%, infections in 24% cases, and peripheral neuropathy in 5%. Discontinuation of treatment was caused by progression in 50%, adverse events in 31%, and intended bridging to CAR-T therapy in 19%. Conclusion Although the outcome of patients is worse than in GO29365 trial, the use of Pola-BR regimen in the real world demonstrates tolerable toxicity profile and efficacy in transplant-ineligible patients with R/R DLBCL. Moreover, this regimen might represent a perspective option as a bridge to CAR-T therapy.

Citovat

VODICKA, Prokop, Katerina BENESOVA, Andrea JANÍKOVÁ, Vit PROCHAZKA, David BELADA, Heidi MOCIKOVA, Katerina STEINEROVA, Juraj DURAS, Josef KARBAN, Veronika HANACKOVA, Alice SYKOROVA, Ales OBR a Marek TRNENY. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world. European Journal of Haematology. Hoboken: Wiley-Blackwell, 2022, roč. 109, č. 2, s. 162-165. ISSN 0902-4441. Dostupné z: https://dx.doi.org/10.1111/ejh.13784.

@article{2249571,
   author = {Vodicka, Prokop and Benesova, Katerina and Janíková, Andrea and Prochazka, Vit and Belada, David and Mocikova, Heidi and Steinerova, Katerina and Duras, Juraj and Karban, Josef and Hanackova, Veronika and Sykorova, Alice and Obr, Ales and Trneny, Marek},
   article_location = {Hoboken},
   article_number = {2},
   doi = {http://dx.doi.org/10.1111/ejh.13784},
   keywords = {DLBCL; polatuzumab vedotin; real world},
   language = {eng},
   issn = {0902-4441},
   journal = {European Journal of Haematology},
   title = {Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/ejh.13784},
   volume = {109},
   year = {2022}
}

TY  - JOUR
ID  - 2249571
AU  - Vodicka, Prokop - Benesova, Katerina - Janíková, Andrea - Prochazka, Vit - Belada, David - Mocikova, Heidi - Steinerova, Katerina - Duras, Juraj - Karban, Josef - Hanackova, Veronika - Sykorova, Alice - Obr, Ales - Trneny, Marek
PY  - 2022
TI  - Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world
JF  - European Journal of Haematology
VL  - 109
IS  - 2
SP  - 162-165
EP  - 162-165
PB  - Wiley-Blackwell
SN  - 09024441
KW  - DLBCL
KW  - polatuzumab vedotin
KW  - real world
UR  - https://onlinelibrary.wiley.com/doi/10.1111/ejh.13784
N2  - Objectives Polatuzumab vedotin with bendamustine and rituximab (Pola-BR) was approved for treatment of transplant-ineligible patients with relapsed/refractory DLBCL (R/R DLBCL). However, the number of patients treated in the GO29365 trial including the extension cohort was limited, and more data evaluating the efficacy of this treatment regimen is needed. Methods We analyzed 21 patients with R/R DLBCL to determine real-life efficacy and safety of Pola-BR regimen. Data of all patients entered the database of the NiHiL project (NCT03199066). Results Median overall survival was 8.7 months, and progression-free survival 3.8 months. The overall response rate was 33%. Grade 3-4 neutropenia was detected in 29%, thrombocytopenia in 38%, anemia in 19%, infections in 24% cases, and peripheral neuropathy in 5%. Discontinuation of treatment was caused by progression in 50%, adverse events in 31%, and intended bridging to CAR-T therapy in 19%. Conclusion Although the outcome of patients is worse than in GO29365 trial, the use of Pola-BR regimen in the real world demonstrates tolerable toxicity profile and efficacy in transplant-ineligible patients with R/R DLBCL. Moreover, this regimen might represent a perspective option as a bridge to CAR-T therapy.
ER  -

VODICKA, Prokop, Katerina BENESOVA, Andrea JANÍKOVÁ, Vit PROCHAZKA, David BELADA, Heidi MOCIKOVA, Katerina STEINEROVA, Juraj DURAS, Josef KARBAN, Veronika HANACKOVA, Alice SYKOROVA, Ales OBR a Marek TRNENY. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world. \textit{European Journal of Haematology}. Hoboken: Wiley-Blackwell, 2022, roč.~109, č.~2, s.~162-165. ISSN~0902-4441. Dostupné z: https://dx.doi.org/10.1111/ejh.13784.

Podrobný výpis o publikaci